GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » Shares Outstanding (EOP)

Nexien BioPharma (Nexien BioPharma) Shares Outstanding (EOP) : 65.27 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Nexien BioPharma Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Nexien BioPharma's shares outstanding for the quarter that ended in Dec. 2023 was 65.27 Mil.

Nexien BioPharma's quarterly shares outstanding increased from Sep. 2023 (64.77 Mil) to Dec. 2023 (65.27 Mil). It means Nexien BioPharma issued new shares from Sep. 2023 to Dec. 2023 .

Nexien BioPharma's annual shares outstanding increased from Jun. 2022 (60.52 Mil) to Jun. 2023 (64.02 Mil). It means Nexien BioPharma issued new shares from Jun. 2022 to Jun. 2023 .


Nexien BioPharma Shares Outstanding (EOP) Historical Data

The historical data trend for Nexien BioPharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexien BioPharma Shares Outstanding (EOP) Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shares Outstanding (EOP)
Get a 7-Day Free Trial 53.51 53.98 55.77 60.52 64.02

Nexien BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.02 62.77 64.02 64.77 65.27

Competitive Comparison of Nexien BioPharma's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexien BioPharma's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Nexien BioPharma's Shares Outstanding (EOP) falls into.



Nexien BioPharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Nexien BioPharma  (OTCPK:NXEN) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Nexien BioPharma Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Nexien BioPharma's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexien BioPharma (Nexien BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is a researcher and developer of cannabinoid-based pharmaceutical for various medical conditions and disorders, all under U.S. Food and Drug Administration development pathways.
Executives
Jeffrey Friedland other: Former 10% Owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Usa Inc. 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Inc. 10 percent owner 4340 E. KENTUCKY AVE., SUITE 206, GLENDALE CO 80246
Joseph F Aceto officer: VP Legal & IP Counsel 1617 NEWARK ROAD, KENNETT SQUARE PA 19348
Jeremy Robert Reeh officer: VP Translational Research 11 TANKARD LANE, WASHINGTON CROSSING PA 18977
Alexander Michael Wasyl director, officer: Chief Executive Officer 31 BEIDLER DRIVE, WASHINGTON CROSSING PA 18977
Frank J Manganella officer: VP Corporate Development 148-26 10TH AVENUE, WHITESTONE NY 11357
Clark Courtney Lynne director PO BOX 7801, ASPEN CO 81612
Lindy Snider director 408 BARBARA LANE, BRYN MAWR PA 19010
Robert I Goldfarb officer: Chief Operating Officer 230 GOLDEN BEACH DRIVE, GOLDEN BEACH FL 33160
Evan L Wasoff officer: Chief Financial Officer 101 WINGER DRIVE, NEDERLAND CO 80466
Alain D Bankier director 150 COLUMBUS AVENUE APT 17F, NEW YORK NY 10023
Richard S Greenberg director, 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Ivo Heiden director, 10 percent owner 2275 HUNTINGTON DRIVE, SUITE 851, SAN MARINO CA 91108